摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氨基-4-氰基苯基硼酸盐酸盐 | 850568-47-7

中文名称
2-氨基-4-氰基苯基硼酸盐酸盐
中文别名
2-氨基-4-氰基苯硼酸盐酸盐
英文名称
(2-amino-4-cyanophenyl)boronic acid hydrochloride
英文别名
2-amino-3-cyanophenylboronic acid hydrochloride;2-amino-4-cyanophenylboronic acid hydrochloric acid salt;2-Amino-4-cyanobenzeneboronic acid hydrochloride;(2-amino-4-cyanophenyl)boronic acid;hydrochloride
2-氨基-4-氰基苯基硼酸盐酸盐化学式
CAS
850568-47-7
化学式
C7H7BN2O2*ClH
mdl
——
分子量
198.417
InChiKey
XTCOKKVEUFHXBE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    214-218

计算性质

  • 辛醇/水分配系数(LogP):
    -0.76
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    90.3
  • 氢给体数:
    4
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi

SDS

SDS:16cd053b21c5147e8200167ec08356f0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Amino-4-cyanophenylboronic acid, HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-4-cyanophenylboronic acid, HCl
CAS number: 850568-47-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H8BClN2O2
Molecular weight: 198.4

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-氨基-4-氰基苯基硼酸盐酸盐3-溴异烟酸乙酯(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloridesodium acetate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 18.0h, 生成 5-oxo-5,6-dihydrobenzo[c][2,6]naphthyridine-8-carbonitrile
    参考文献:
    名称:
    发现和SAR的第一个临床阶段蛋白激酶CK2抑制剂5-(3-氯苯基氨基)苯并[ c ] [2,6]萘吡啶-8-羧酸(CX-4945)
    摘要:
    本文中,我们对CX-4945(25n)的发现进行了编年史,CX-4945是蛋白激酶CK2的一流的,口服可生物利用的ATP竞争性抑制剂,在癌症的临床试验中得到了证实。CK2长期以来一直被认为是主要的癌症药物靶标,因为CK2的失调和过度表达在促进癌症的生存和抗凋亡途径中起着重要的作用。这些生物学特性以及CK2的小ATP结合位点对选择性抑制剂设计的适用性,使我们开发出了新型的癌症治疗剂。导致25n(K i = 0.38 nM)的最优化是通过分子建模指导的,这表明25n的强结合由疏水相互作用,与Lys68形成的离子桥以及与铰链区的氢键结合而成。发现25n具有高度选择性,可跨物种口服生物利用(20-51%),并且在异种移植模型中有效。25n的发现将首次使CK2在人类中具有治疗靶向性。
    DOI:
    10.1021/jm101251q
点击查看最新优质反应信息

文献信息

  • Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2
    作者:Moses Moustakim、Kerstin Riedel、Marion Schuller、Andrè P. Gehring、Octovia P. Monteiro、Sarah P. Martin、Oleg Fedorov、Jag Heer、Darren J. Dixon、Jonathan M. Elkins、Stefan Knapp、Franz Bracher、Paul E. Brennan
    DOI:10.1016/j.bmc.2018.03.020
    日期:2018.7
    unclear. A medium throughput screen led to the identification of N-(2(-9H-carbazol-1-yl)phenyl)acetamide (GeA-69, 1) as a novel allosteric PARP14 MD2 (second MD of PARP14) inhibitor. We herein report medicinal chemistry around this novel chemotype to afford a sub-micromolar PARP14 MD2 inhibitor. This chemical series provides a novel starting point for further development of PARP14 chemical probes.
    聚腺苷二磷酸核糖聚合酶14(PARP14)已牵涉到DNA损伤反应途径中的同源重组。PARP14包含三个(ADP核糖结合)宏域(MD),尚不清楚其对病理学中整个PARP14功能的确切贡献。中等通量筛选导致鉴定出N-(2(-9H-咔唑-1-基)苯基)乙酰胺(GeA-69,1)作为新型变构PARP14 MD2(PARP14的第二个MD)抑制剂。我们在此报告了围绕这种新型化学型的药物化学,以提供亚微摩尔的PARP14 MD2抑制剂。该化学系列为进一步开发PARP14化学探针提供了新的起点。
  • Macrocyclic Compounds As Antiviral Agents
    申请人:Harper Steven
    公开号:US20100183551A1
    公开(公告)日:2010-07-22
    A class of macrocyclic compounds of formula (I), wherein R 1 , R 3 , R 4 , R a , R b , A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. Formula (I):
    提供一类宏环化合物的化学式(I),其中R1、R3、R4、Ra、Rb、A、Z、Y、X、M、W、n和m如下所定义,这些化合物可作为病毒蛋白酶的抑制剂,特别是对乙型肝炎病毒(HCV)NS3蛋白酶的抑制剂。还提供了合成和使用这类宏环化合物用于治疗或预防HCV感染的方法。化学式(I):
  • PROTEIN KINASE MODULATORS
    申请人:CHUA Peter C.
    公开号:US20090239859A1
    公开(公告)日:2009-09-24
    The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
    该发明部分涉及具有特定生物活性的分子,包括但不限于抑制细胞增殖、调节蛋白激酶活性和调节聚合酶活性。该发明的分子可以调节Pim激酶活性和/或FMS样酪氨酸激酶(Flt)活性。该发明还涉及使用这些分子的方法。
  • SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
    申请人:CHUA Peter
    公开号:US20090264423A2
    公开(公告)日:2009-10-22
    The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such molecules.
    本发明涉及具有某些生物活性的分子,包括但不限于抑制细胞增殖、调节蛋白激酶活性和调节聚合酶活性。本发明的分子可以调节酪蛋白激酶(CK)活性和/或聚(ADP-核糖)聚合酶(PARP)活性。本发明还涉及使用这些分子的方法。
  • Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
    申请人:Cylene Pharmaceuticals, Inc.
    公开号:US07956064B2
    公开(公告)日:2011-06-07
    The invention relates in part to fused tricyclic compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. The fused tricyclic compounds of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such fused tricyclic compounds.
    本发明部分涉及具有特定生物活性的融合三环化合物,包括但不限于抑制细胞增殖、调节蛋白激酶活性和调节聚合酶活性。本发明的融合三环化合物可以调节酪蛋白激酶(CK)活性和/或聚腺苷酸二磷酸核糖聚合酶(PARP)活性。本发明部分还涉及使用这种融合三环化合物的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐